Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787144 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4ETSHRPOLBOPRK1 | |
| SCHEMBL21787147 | 0.91 | MME (0.39) | ALDH1A1KDM4ETSHRPOLBNPY1R | |
| SCHEMBL21787357 | 0.90 | HTR2A (0.44) | ALDH1A1TSHRPOLBOPRK1NPY1R | |
| SCHEMBL24221036 | 0.89 | OPRK1 (0.36) | ALDH1A1KDM4ETSHRPOLBOPRK1 | |
| SCHEMBL23052535 | 0.89 | MME (0.43) | ALDH1A1KDM4ETSHRPOLBOPRK1 | |
| SCHEMBL21081697 | 0.89 | MME (0.43) | ALDH1A1KDM4ETSHRPOLBOPRK1 | |
| SCHEMBL24677905 | 0.89 | TSHR (0.39) | ALDH1A1TSHRPOLBNPY1RNPY5R | |
| SCHEMBL22799503 | 0.88 | KDM1A (0.40) | TSHRPOLBNPY1RNPY5RMME | |
| SCHEMBL21081676 | 0.83 | KDM1A (0.38) | ALDH1A1KDM4ETSHRPOLBNPY1R | |
| SCHEMBL21081701 | 0.81 | MME (0.35) | ALDH1A1TSHRPOLBNPY1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-11717574-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-11717574-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
| US-20210060172-A1 | THERAPEUTIC DENDRIMERS | ASTRAZENECA AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-10888624-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2021-01-12 | — | — | US | disclosed |
| US-20200392295-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2020-12-17 | — | — | US | disclosed |
| US-20200069810-A1 | THERAPEUTIC DENDRIMERS | ASTRAZENECA PHARMACEUTICALS LP | 2020-03-05 | — | — | US | disclosed |
| US-10314920-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314920-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | ALDH1A1 342/4885KDM4E 4646/4885TSHR 2456/4885 |
| US-11717574-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | ALDH1A1 342/4885KDM4E 4646/4885TSHR 2456/4885 |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | ALDH1A1 342/4885KDM4E 4248/4885TSHR 1466/4885 |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | ALDH1A1 2061/4885KDM4E 465/4885TSHR 2979/4885 |
| US-20210060172-A1 | THERAPEUTIC DENDRIMERS | CD44, ITGAV, FOLR1 | ALDH1A1 342/4885KDM4E 4646/4885TSHR 2456/4885 |
| US-20200392295-A1 | THERAPEUTIC DENDRIMER | CLTA, DCK, CLTB | ALDH1A1 1760/4885KDM4E 2036/4885TSHR 3197/4885 |
| US-10888624-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | ALDH1A1 342/4885KDM4E 4646/4885TSHR 2456/4885 |
| US-20200069810-A1 | THERAPEUTIC DENDRIMERS | CD44, ITGAV, FOLR1 | ALDH1A1 342/4885KDM4E 4646/4885TSHR 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.